biotech - MarketMinute

Inhibrx stock

Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly positive topline results from its registrational trial of ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma. This monumental achievement positions ozekibart as a potential

biotech

Connecticut Biotech Firm Intensity Therapeutics Navigates Critical Reverse Stock Split

Shelton, CT – October 24, 2025 – Intensity Therapeutics Inc. (NASDAQ: INTS), a clinical-stage biotechnology company based in Shelton, Connecticut, is proceeding with a pivotal reverse stock split plan, a strategic corporate action aimed at shoring up its financial standing and maintaining its coveted listing on The Nasdaq Stock Market. This move

Avadel Pharmaceuticals

Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to

Nurix Therapeutics

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase

Adaptimmune

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Capital Market. The news triggered an immediate and dramatic 62.5% plunge in the company's stock

Turnstone Biologics

Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality

October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of its stock reaching a $100 valuation stands in stark contrast to its current precarious financial and operational state. Despite the transformative

biotech

Omeros Rockets Skyward on $2.1 Billion Novo Nordisk Deal, Reshaping Biotech Landscape

In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a colossal licensing agreement with pharmaceutical titan Novo Nordisk (CPH: NOVO B). The deal, potentially valued at up to $2.1 billion,

Krystal Biotech

Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets

The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and intermittent volatility. In this nuanced environment, a compelling narrative is emerging around growth stocks exhibiting significant insider ownership. This

Beam Therapeutics

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

New York, NY – October 9, 2025 – In a significant move set to ripple through the biotech sector, Jefferies has initiated coverage of Beam Therapeutics (NASDAQ: BEAM) with a coveted "Buy" rating. This optimistic outlook is underpinned by the firm's strong conviction in Beam's innovative

Zevra Therapeutics

Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors

Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early October 2025, the biopharmaceutical company, focused on rare diseases, is demonstrating a positive trajectory, fueled by critical regulatory milestones, impressive

Leap Therapeutics

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,

Nanobiotix

Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes

Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed